首页> 美国卫生研究院文献>PLoS Clinical Trials >A Critical Evaluation of microRNA Biomarkers in Non-Neoplastic Disease
【2h】

A Critical Evaluation of microRNA Biomarkers in Non-Neoplastic Disease

机译:对非赘生性疾病中microRNA生物标志物的关键评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundMicroRNAs (miRNAs) are small (∼22-nt), stable RNAs that critically modulate post-transcriptional gene regulation. MicroRNAs can be found in the blood as components of serum, plasma and peripheral blood mononuclear cells (PBMCs). Many microRNAs have been reported to be specific biomarkers in a variety of non-neoplastic diseases. To date, no one has globally evaluated these proposed clinical biomarkers for general quality or disease specificity. We hypothesized that the cellular source of circulating microRNAs should correlate with cells involved in specific non-neoplastic disease processes. Appropriate cell expression data would inform on the quality and usefulness of each microRNA as a biomarker for specific diseases. We further hypothesized a useful clinical microRNA biomarker would have specificity to a single disease.
机译:背景MicroRNA(miRNA)是很小的(〜22-nt)稳定RNA,可关键地调节转录后基因的调控。在血液中可以发现MicroRNA,它们是血清,血浆和外周血单核细胞(PBMC)的成分。据报道,许多microRNA是多种非肿瘤性疾病的特异性生物标志物。迄今为止,还没有人针对总体质量或疾病特异性对这些提议的临床生物标志物进行全球评估。我们假设循环microRNA的细胞来源应与参与特定非肿瘤性疾病过程的细胞相关。适当的细胞表达数据将说明每种microRNA作为特定疾病生物标记物的质量和有用性。我们进一步假设有用的临床microRNA生物标记物将对单一疾病具有特异性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号